Sarepta disputes analyst's predictions on eteplirsen IP tangles
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics CEO Chris Garabedian on 2 December took issue with an analyst's prediction that BioMarin Pharmaceuticals, which is acquiring the former firm's potential competitor Prosensa, would likely assert its US intellectual property rights to keep etelipersen off the American market or possibly demand sales royalties.